Published in Naunyn Schmiedebergs Arch Pharmacol on February 10, 2004
The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders. Br J Pharmacol (2013) 1.04
Kynurenic acid synthesis in bovine retinal slices--effect of glutamate agonists. J Neural Transm (Vienna) (2006) 0.77
Kynurenine Aminotransferase Isozyme Inhibitors: A Review. Int J Mol Sci (2016) 0.75
A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther (1949) 13.89
An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res (1982) 2.99
The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci (2001) 2.61
Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci U S A (1997) 2.32
Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci (2003) 2.21
Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex. J Neurol Sci (1992) 1.79
Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. Eur J Pharmacol (1988) 1.37
Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. Eur J Pharmacol (1999) 1.30
Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neurosci Lett (1984) 1.29
Kynurenine pathway abnormalities in Parkinson's disease. Neurology (1992) 1.14
Homocysteine and risk of open-angle glaucoma. J Neural Transm (Vienna) (2002) 1.14
Modulation of morphine antinociception by peripheral [Leu5]enkephalin: a synergistic interaction. Eur J Pharmacol (1990) 1.14
Identification and quantification of kynurenic acid in human brain tissue. Brain Res (1988) 1.12
Characterization of rat brain kynurenine aminotransferases I and II. J Neurosci Res (1997) 1.08
Two kynurenine aminotransferases in human brain. Brain Res (1991) 1.07
Rat brain slices produce and liberate kynurenic acid upon exposure to L-kynurenine. J Neurochem (1989) 1.02
Purification and characterization of kynurenine-pyruvate aminotransferase from rat kidney and brain. Brain Res (1990) 1.00
Measurement of kynurenic acid in mammalian brain extracts and cerebrospinal fluid by high-performance liquid chromatography with fluorometric and coulometric electrode array detection. Anal Biochem (1990) 0.92
Brain-specific modulation of kynurenic acid synthesis in the rat. J Neurochem (1997) 0.91
Characterization of human brain kynurenine aminotransferases using [3H]kynurenine as a substrate. Neuroscience (1993) 0.87
Homocysteine levels during fasting and after methionine loading in adolescents with diabetic retinopathy and nephropathy. J Pediatr (2000) 0.85
Localization of kynurenine aminotransferase immunoreactivity in the rat hippocampus. J Comp Neurol (1992) 0.83
Immunocytochemical localization of kynurenine aminotransferase in the rat striatum: a light and electron microscopic study. J Comp Neurol (1992) 0.81
Endothelium-dependent production and liberation of kynurenic acid by rat aortic rings exposed to L-kynurenine. Eur J Pharmacol (2002) 0.80
2-Aminoadipate-2-oxoglutarate aminotransferase isoenzymes in human liver: a plausible physiological role in lysine and tryptophan metabolism. Enzyme Protein (1993) 0.78
Some metabotropic glutamate receptor ligands reduce kynurenate synthesis in rats by intracellular inhibition of kynurenine aminotransferase II. J Neurochem (2000) 0.78
Studies on cerebrospinal fluid kynurenic acid concentrations in epileptic children. Brain Dev (1996) 0.77
Immuno-localization of kynurenine aminotransferase (KAT) in the rat medulla and spinal cord. Neuroreport (1997) 0.77
Modulation of extracellular kynurenic acid content by excitatory amino acids in primary cultures of rat astrocytes. Adv Exp Med Biol (1996) 0.76
Brain-specific control of kynurenic acid production by depolarizing agents. Adv Exp Med Biol (1991) 0.76
Impairment of brain kynurenic acid production by glutamate metabotropic receptor agonists. Neuroreport (1997) 0.76
Regulation of kynurenic acid synthesis in C6 glioma cells. J Neurosci Res (2002) 0.76
Presence of kynurenic acid and kynurenine aminotransferases in the inner retina. Neuroreport (2001) 0.75
Alterations of kynurenic acid content in the retina in response to retinal ganglion cell damage. Vision Res (2003) 0.75
The influence of ketone bodies and glucose on interferon, tumor necrosis factor production and NO release in bovine aorta endothelial cells. Vet Immunol Immunopathol (2000) 0.75
Kynurenate forming enzymes in liver, kidney and brain. Adv Exp Med Biol (1991) 0.75
Formation of endogenous glutamatergic receptors antagonist kynurenic acid--differences between cortical and spinal cord slices. Brain Res (2000) 0.75
Sedative and anticonvulsant drugs suppress postnatal neurogenesis. Ann Neurol (2008) 2.46
CNGB3 mutations account for 50% of all cases with autosomal recessive achromatopsia. Eur J Hum Genet (2005) 2.37
In vivo confocal imaging of the retina in animal models using scanning laser ophthalmoscopy. Vision Res (2005) 2.02
Simultaneous correction of post-traumatic aphakia and aniridia with the use of artificial iris and IOL implantation. Graefes Arch Clin Exp Ophthalmol (2013) 2.01
Photoreceptor cell death mechanisms in inherited retinal degeneration. Mol Neurobiol (2008) 1.94
TRPM1 is mutated in patients with autosomal-recessive complete congenital stationary night blindness. Am J Hum Genet (2009) 1.93
PDZD7 is a modifier of retinal disease and a contributor to digenic Usher syndrome. J Clin Invest (2010) 1.85
Mutations in CABP4, the gene encoding the Ca2+-binding protein 4, cause autosomal recessive night blindness. Am J Hum Genet (2006) 1.77
Artificial vision with wirelessly powered subretinal electronic implant alpha-IMS. Proc Biol Sci (2013) 1.63
Spatial resolution and perception of patterns mediated by a subretinal 16-electrode array in patients blinded by hereditary retinal dystrophies. Invest Ophthalmol Vis Sci (2011) 1.52
Mutation analysis of NR2E3 and NRL genes in Enhanced S Cone Syndrome. Hum Mutat (2004) 1.45
Dizocilpine improves beneficial effects of cholinergic antagonists in anticholinesterase-treated mice. Toxicol Sci (2003) 1.45
Retinal neurodegeneration in the DBA/2J mouse-a model for ocular hypertension. Acta Neuropathol (2004) 1.44
IQCB1 mutations in patients with leber congenital amaurosis. Invest Ophthalmol Vis Sci (2011) 1.43
Viagra (sildenafil citrate) and ophthalmology. Prog Retin Eye Res (2002) 1.37
Mutations in TOPORS cause autosomal dominant retinitis pigmentosa with perivascular retinal pigment epithelium atrophy. Am J Hum Genet (2007) 1.33
Expression of glutamate receptor subunits in human cancers. Histochem Cell Biol (2009) 1.31
NMDA antagonist inhibits the extracellular signal-regulated kinase pathway and suppresses cancer growth. Proc Natl Acad Sci U S A (2005) 1.30
Mechanisms leading to disseminated apoptosis following NMDA receptor blockade in the developing rat brain. Neurobiol Dis (2004) 1.30
Nonsense mutations in FAM161A cause RP28-associated recessive retinitis pigmentosa. Am J Hum Genet (2010) 1.29
Mutation in the auxiliary calcium-channel subunit CACNA2D4 causes autosomal recessive cone dystrophy. Am J Hum Genet (2006) 1.29
Retinal degeneration associated with RDH12 mutations results from decreased 11-cis retinal synthesis due to disruption of the visual cycle. Hum Mol Genet (2005) 1.26
Whole-exome sequencing identifies mutations in GPR179 leading to autosomal-recessive complete congenital stationary night blindness. Am J Hum Genet (2012) 1.25
Mutant carbonic anhydrase 4 impairs pH regulation and causes retinal photoreceptor degeneration. Hum Mol Genet (2004) 1.22
Transcorneal electrical stimulation for patients with retinitis pigmentosa: a prospective, randomized, sham-controlled exploratory study. Invest Ophthalmol Vis Sci (2011) 1.21
Mutation analysis identifies GUCY2D as the major gene responsible for autosomal dominant progressive cone degeneration. Invest Ophthalmol Vis Sci (2008) 1.21
Cone dystrophy with supernormal rod response is strictly associated with mutations in KCNV2. Invest Ophthalmol Vis Sci (2008) 1.20
Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients. Int Ophthalmol (2007) 1.18
Mitochondrial aspartate aminotransferase: a third kynurenate-producing enzyme in the mammalian brain. J Neurochem (2007) 1.15
Basic quantitative assessment of visual performance in patients with very low vision. Invest Ophthalmol Vis Sci (2009) 1.15
Mutations in the GUCA1A gene involved in hereditary cone dystrophies impair calcium-mediated regulation of guanylate cyclase. Hum Mutat (2009) 1.14
Mutations in C8orf37, encoding a ciliary protein, are associated with autosomal-recessive retinal dystrophies with early macular involvement. Am J Hum Genet (2011) 1.12
PARP1 gene knock-out increases resistance to retinal degeneration without affecting retinal function. PLoS One (2010) 1.10
Genotyping microarray for CSNB-associated genes. Invest Ophthalmol Vis Sci (2009) 1.10
Ectopic norrin induces growth of ocular capillaries and restores normal retinal angiogenesis in Norrie disease mutant mice. J Neurosci (2005) 1.10
Cataract prevalence and prevention in Europe: a literature review. Acta Ophthalmol (2012) 1.08
Calpain and PARP activation during photoreceptor cell death in P23H and S334ter rhodopsin mutant rats. PLoS One (2011) 1.08
Novel types of mutation in the choroideremia ( CHM) gene: a full-length L1 insertion and an intronic mutation activating a cryptic exon. Hum Genet (2003) 1.07
Long-term follow-up of retinitis pigmentosa patients with multifocal electroretinography. Invest Ophthalmol Vis Sci (2008) 1.07
Visual resolution with retinal implants estimated from recordings in cat visual cortex. Vision Res (2006) 1.07
Large deletions of the KCNV2 gene are common in patients with cone dystrophy with supernormal rod response. Hum Mutat (2011) 1.06
Restoration of useful vision up to letter recognition capabilities using subretinal microphotodiodes. Conf Proc IEEE Eng Med Biol Soc (2010) 1.05
Visual short-term effects of Viagra: double-blind study in healthy young subjects. Am J Ophthalmol (2004) 1.04
Epidemiology of major eye diseases leading to blindness in Europe: a literature review. Ophthalmic Res (2011) 1.04
Geographical Information System (GIS) as a tool for monitoring and analysing pesticide pollution and its impact on public health. Ann Agric Environ Med (2004) 1.03
Thirty distinct CACNA1F mutations in 33 families with incomplete type of XLCSNB and Cacna1f expression profiling in mouse retina. Eur J Hum Genet (2002) 1.03
Functional outcome in subretinal electronic implants depends on foveal eccentricity. Invest Ophthalmol Vis Sci (2013) 1.02
ABCA4 gene analysis in patients with autosomal recessive cone and cone rod dystrophies. Eur J Hum Genet (2008) 1.02
Homocysteine in tear fluid of patients with pseudoexfoliation glaucoma. J Glaucoma (2007) 1.02
Investigation of thermal effects of infrared lasers on the rabbit retina: a study in the course of development of an active subretinal prosthesis. Graefes Arch Clin Exp Ophthalmol (2007) 1.00
Neuroprotective effects of tempol on retinal ganglion cells in a partial optic nerve crush rat model with and without iron load. Exp Eye Res (2009) 1.00
Administration of novel dyes for intraocular surgery: an in vivo toxicity animal study. Invest Ophthalmol Vis Sci (2006) 1.00
Decreased catalytic activity and altered activation properties of PDE6C mutants associated with autosomal recessive achromatopsia. Hum Mol Genet (2010) 0.98
Quantifying fixation in patients with Stargardt disease. Vision Res (2007) 0.98
Safety and efficacy of subretinal visual implants in humans: methodological aspects. Clin Exp Optom (2012) 0.98
Compound subretinal prostheses with extra-ocular parts designed for human trials: successful long-term implantation in pigs. Graefes Arch Clin Exp Ophthalmol (2007) 0.97
Kynurenic acid synthesis and kynurenine aminotransferases expression in colon derived normal and cancer cells. Scand J Gastroenterol (2011) 0.97
High concentration of kynurenic acid in bile and pancreatic juice. Amino Acids (2008) 0.97
Subretinal electrical stimulation of the rabbit retina with acutely implanted electrode arrays. Graefes Arch Clin Exp Ophthalmol (2004) 0.96
Usher syndrome type 1 due to missense mutations on both CDH23 alleles: investigation of mRNA splicing. Hum Mutat (2008) 0.96
Stereotactic fractionated radiotherapy in patients with optic nerve sheath meningioma. Int J Radiat Oncol Biol Phys (2002) 0.95
Phenotypic expression of the complete type of X-linked congenital stationary night blindness in patients with different mutations in the NYX gene. Graefes Arch Clin Exp Ophthalmol (2002) 0.94
Economic evaluation of orthoptic screening: results of a field study in 121 German kindergartens. Invest Ophthalmol Vis Sci (2002) 0.94
cGMP-dependent cone photoreceptor degeneration in the cpfl1 mouse retina. J Comp Neurol (2010) 0.94
Age-related changes in retinal functional topography. Invest Ophthalmol Vis Sci (2008) 0.94
Early electroretinographic features of streptozotocin-induced diabetic retinopathy. Clin Experiment Ophthalmol (2007) 0.93
Abnormalities of the long flash ERG in congenital stationary night blindness of the Schubert-Bornschein type. Vision Res (2002) 0.93
Mapping of retinal function in Best macular dystrophy using multifocal electroretinography. Vision Res (2002) 0.92
Variant phenotypes of incomplete achromatopsia in two cousins with GNAT2 gene mutations. Invest Ophthalmol Vis Sci (2004) 0.91
Electroretinography as a screening method for mutations causing retinal dysfunction in mice. Invest Ophthalmol Vis Sci (2004) 0.91
Scotopic threshold responses to infrared irradiation in cats. Vision Res (2005) 0.90
Activation of kynurenine pathway in ex vivo fibroblasts from patients with bipolar disorder or schizophrenia: cytokine challenge increases production of 3-hydroxykynurenine. J Psychiatr Res (2013) 0.90
Fluoxetine inhibits the extracellular signal regulated kinase pathway and suppresses growth of cancer cells. Cancer Biol Ther (2008) 0.90
ATP-induced non-neuronal cell permeabilization in the rat inner retina. J Neurosci (2004) 0.89
Alterations of amino acids and glutamate transport in the DBA/2J mouse retina; possible clues to degeneration. Graefes Arch Clin Exp Ophthalmol (2007) 0.89
Neuroprotection by acetoacetate and β-hydroxybutyrate against NMDA-induced RGC damage in rat--possible involvement of kynurenic acid. Graefes Arch Clin Exp Ophthalmol (2010) 0.89
Apoptosis induction in human glioblastoma multiforme T98G cells upon temozolomide and quercetin treatment. Tumour Biol (2013) 0.89
The phenotype of early-onset retinal degeneration in persons with RDH12 mutations. Invest Ophthalmol Vis Sci (2007) 0.89
Phosphenes electrically evoked with DTL electrodes: a study in patients with retinitis pigmentosa, glaucoma, and homonymous visual field loss and normal subjects. Invest Ophthalmol Vis Sci (2006) 0.89
Transcorneal electrical stimulation shows neuroprotective effects in retinas of light-exposed rats. Invest Ophthalmol Vis Sci (2012) 0.89
Visual field constriction and electrophysiological changes associated with vigabatrin. Doc Ophthalmol (2002) 0.89
Presence of kynurenic acid in food and honeybee products. Amino Acids (2008) 0.88
Kynurenic Acid in the digestive system-new facts, new challenges. Int J Tryptophan Res (2013) 0.87
Toxicity testing of the VEGF inhibitors bevacizumab, ranibizumab and pegaptanib in rats both with and without prior retinal ganglion cell damage. Acta Ophthalmol (2010) 0.87
Effects of pro-inflammatory cytokines on expression of kynurenine pathway enzymes in human dermal fibroblasts. J Inflamm (Lond) (2011) 0.87
Molecular basis of an inherited form of incomplete achromatopsia. J Neurosci (2004) 0.87
A comparison of the performance of three visual evoked potential-based methods to estimate visual acuity. Doc Ophthalmol (2012) 0.87
Kynurenic acid protects against the homocysteine-induced impairment of endothelial cells. Pharmacol Rep (2009) 0.86
Temozolomide, quercetin and cell death in the MOGGCCM astrocytoma cell line. Chem Biol Interact (2010) 0.86
[Effect of 17 beta-estradiol and phytoestrogen daidzein on the proliferation of pubocervical fascia and skin fibroblasts derived from women suffering from stress urinary incontinence]. Ginekol Pol (2003) 0.86